Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CMMB with free AI briefings, catalyst countdowns, and dilution alerts.

CMMB · Chemomab Therapeutics Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$20.8M Cash on Hand
9.7mo Cash Runway
Follow CMMB by email Get an email when CMMB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CMMB, unsubscribe in one click. Privacy

📣 What CMMB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-human CCL24 monoclonal antibody (CM-101) Primary Sclerosing Cholangitis Phase 2 · NCT04595825 Completed
Anti-human CCL24 monoclonal antibody (CM-101) - Nonalcoholic Fatty Liver Disease Phase 1 · NCT06044467 Completed
ZD0101 Nonalcoholic Steatohepatitis (NASH) Phase 1 · NCT06037577 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CMMB holds $20.8M in cash and short-term investments (as of Mar 31, 2023) and burns about $6.4M/quarter from operations, an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CMMB files for a raise →

👥 Who Owns CMMB

Insiders 0% Other 5%+ holders 27.1% Institutions (20 holders) 20.5% Public and other holders 52.4%
HolderTypeShares% of sharesAs of
HBM Healthcare Investments (Cayman) Ltd. 5%+ holder (13D) 80,971,680 14.07% 2026-09-07
Scipher Medicine Corp 5%+ holder (13D) 74,576,240 12.96% 2026-11-03
Touchstone Global Investments Pty Ltd 5%+ holder (13G) 377,814 0.07% 2026-08-07
Neil Harris Cohen
Director · +54,785 options
Insider 33,000 0.01% 2026-08-27
John Lawler
Chief Development Officer
Insider 20,000 0.00% 2026-03-18
George Adi Mor
Chief Executive Officer, Director
Insider 18,750 0.00% 2026-05-29
Sigal Fatal
Chief Financial Officer
Insider 12,500 0.00% 2026-03-18
Nissim Darvish
Director
Insider 300 0.00% 2026-03-18

Share count 575,381,320 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CMMB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMMB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.